Table 2 Examples of proteomic approaches for characterizing RCC tissue, blood-associated (plasma/serum), or urine specimens
From: Proteomic approaches for characterizing renal cell carcinoma
Biological source | # of samples | Experimental approach | # of differentially expressed targets | Citing report |
|---|---|---|---|---|
Tissue | 50 | Used LFQ approach to identify proteins associated with tumor grade, profiling NAT and ccRCC tissues with Furman grades between 1 and 4 | 105 | [42] |
Tissue | 75 | Employed MALDI-MSI to identify differential expressed proteins associated with the tumor, tumor margin, and NAT regions | 12 | [56] |
Tissue | 194 | Utilized proteogenomic approach; TMT-based quantitation for delineating differential global protein and phosphopeptide/phosphosite profiles between tumors and NATs | 820 | [20] |
Serum | 162 | Profiled the serum peptidome in healthy controls, ccRCC patients, and ccRCC patients before and after surgical resection | 18 | [86] |
Serum | 99 | Examined urine proteome profiles to discriminate ccRCC from healthy controls, benign kidney masses, and non-ccRCC urological tumors | 27 | [80] |
Urine | 254 | Examined serum peptidome profiles to discriminate ccRCC from healthy controls, prioritizing discriminatory clinicopathological-associated features (stage, grade, tumor size) | 15 | [101] |
Urine | 90 | Used LFQ to characterize the urinary proteome of ccRCC patients and healthy controls; stratifying ccRCC patients into good or poor prognosis groups based on Furhman grading | 49 | [92] |
Tissue/EVs | 40 | Used an ex vivo model to profile extracellular vesicles (EVs) derived from ccRCC tumors and NATs | 397 | [112] |